Kirsten Bibbins-Domingo

[3] She is a cardiovascular disease epidemiologist whose work focuses on clinical and public health approaches to prevention, particularly in young adults.

[5] In 2006, Bibbins-Domingo co-founded the UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital, a research center focused on advancing health equity and reducing health disparities in the San Francisco Bay Area, nationally, and globally.

[12] She has led two NIH center grants focused on disparities in diabetes, cardiovascular disease, and stroke in young adulthood.

[13] Her work has examined the population health impact of policy approaches to reduce consumption of salt [14] and sugary beverages.

Bibbins-Domingo published a series of cost-effectiveness analyses on the PCSK-9 inhibitor medications in JAMA and Annals of Internal Medicine.

[5] In 2017, the U.S. Preventive Services Task Force changed their recommendation on PSA testing for prostate cancer[20] and Bibbins-Domingo appeared on PBS in 2017 to describe this decision.

Bibbins-Domingo has received mentoring awards from the Society of General Internal Medicine and UCSF Phillip R. Lee Institute for Health Policy Studies.